Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q4 FY24 Earnings Presentation
19 slides from Glenmark Pharmaceuticals's earnings presentation, May 24, 2024
Slide 1: Stock exchange cover letter
May 24, 2024 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 532296 Ref:
Slide 2: Investor Presentation: Q4 FY24
Investor Presentation: Q4 FY24 24 May 2024
Slide 3: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen
Slide 4: Key Highlights in FY24
Key Highlights in FY24 In the fourth quarter, Glenmark gained 2 positions to be ranked as the 3rd largest company in the Cardiac segment of the Indian Pharmaceutical Market1 • Glenmark’s Europe business continued strong Glenmark completed the divestment of 75% of its growth momentum to record 33.7%
Slide 5: Q4 FY24 Summary
Q4 FY24 Summary Revenue from operations at Rs. 30,630 Mn with growth of 2.1% YoY “This past year has been a period of significant transition and EBITDA of Rs. 5,043 Mn with EBITDA margin of 16.5% transformation for Glenmark. We successfully divested a majority stake in Glenmark Life Sciences, co
Slide 6: FY24 Summary
FY24 Summary Revenue from operations at Rs. 1,18,131 Mn with growth of 2% YoY “This past year has been a period of significant transition and EBITDA margin of 10.1%, lower primarily on account of one-time impact in sales for the India business in Q3 FY24 transformation for Glenmark. We successfu
Slide 7: Consolidated Revenues from Continuing Operations – Q4 FY24
Consolidated Revenues from Continuing Operations – Q4 FY24 Fourth Quarter ended March 31 Third Quarter ended December 31 YoY Growth QoQ Growth Rs Mn FY 2023-24 FY 2022-23 FY 2022-23 (%) (%) India 9,391 8,316 12.9% 2,622 258.2% North America 7,557 8,628 -12.4% 7,629 -0.9% Europe 6,118 6,078 0.7% 6,35
Slide 8: Consolidated Revenues from Continuing Operations – FY24
Consolidated Revenues from Continuing Operations – FY24 Twelve Months ended March 31 YoY Growth Rs Mn FY 2023-24 FY 2022-23 (%) India 33,994 40,463 -16.0% North America 30,943 31,481 -1.7% Europe 24,205 18,097 33.7% Rest of the World1 27,666 23,834 16.1% Total 1,16,807 1,13,876 2.6% Other Revenue 1,
Slide 9: P&L Highlights
P&L Highlights Rs. Mn Q4 FY24 Q4 FY23 FY24 FY23 Revenues from Operations 30,630 30,005 1,18,131 1,15,832 EBITDA 5,043 3,979 11,953 16,350 EBITDA margin (%) 16.5% 13.3% 10.1% 14.1% Other Income (exp) 7,732 -424 8,400 2,889 Exceptional gain (loss) 4,468 7,997 9,010 7,659 Profit Before Tax (PBT) 5,308
Slide 10: Balance Sheet Highlights
Balance Sheet Highlights Total Debt Rs. Mn 31 March 2024 31 March 2023 Gross Debt 9,906 43,477 Cash and Cash Equivalents 16,583 11,592 Net Debt -6,677 31,885 Net Working Capital Rs. Mn 31 March 2024 31 March 2023 Inventory 25,131 23,736 Receivables 18,584 36,652 Payables 25,359 20,004 Net Working Ca
Slide 11: India
29% FY24 India Launched JABRYUS® Revenue (INR million) YoY: -16% Glenmark now ranked 3rd in the (Abrocitinib), a novel molecule Cardiac segment1 for moderate-to-severe AD, in 40,463 partnership with Pfizer 33,994 Key Highlights for Q4 FY24 Glenmark’s India business continued to outperform the over
Slide 12: North America
29% FY24 North America Revenue (INR million) YoY: -1.7% ANDA for gFlovent® pMDI filed 52 ANDAs pending for approval, 30,943 31,481 in May 2024 including 21 Para IV applications Key Highlights for Q4 FY24 Overall business growth remained challenging on account of lack of new product launches and de
Slide 13: Europe
29% FY24 Europe Revenue (INR million) YoY: 33.7% RYALTRIS® continues to scale up Strong growth of 33.7% for FY24 24,205 to increase share across markets 18,097 Key Highlights for Q4 FY24 FY24 FY23 Branded markets in the region performed well, overall growth in the fourth quarter impacted due to so
Slide 14: Rest Of the World (ROW)
29% FY24 Rest Of the World (ROW)1 Revenue (INR million) YoY: 16.1% In-licensed Envafolimab, a novel RYALTRIS® continues to scale up 27,666 PD-L1 inhibitor for Oncology, for to increase share across markets 23,834 ROW markets + India Key Highlights for Q4 FY24 Russia: Strong secondary sales growth
Slide 15: Creating Global Brands – RYALTRIS®
Creating Global Brands – RYALTRIS® As of March 2024, marketing applications for RYALTRIS® have been submitted in Value market shares of RYALTRIS® across key geographies (Top 10 products within “R1A1 – Nasal Corticosteroids more than 80 countries across the world and the product has been without An
Slide 16: Creating Global Brands – Envafolimab & WINLEVI®
Creating Global Brands – Envafolimab & WINLEVI® Envafolimab The Company announced the signing of a license agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd (Jiangsu Alphamab) and 3D Medicines (Beijing) Co., Ltd. (3DMed) for Envafolimab for India, Asia Pacific, Middle East and Africa, Ru
Slide 17: Ichnos Glenmark Innovation
ICHNOS GLENMARK INNOVATION IGI Biologics Pipeline - First Wave Focuses on T-Cell Engagers and IGI Biologic Assets in Autoimmune (AI) Disease Macrophage Modulators for Oncology MOLECULE MECHANISM/CLASS PHASE/STATUS LEAD INDICATION Molecule Potential Phase Status Mechanism/Class Indications ISB 2001 B
Slide 18: Key objectives for FY25
Key objectives for FY25 1 Consolidated revenue: Rs. 1,35,000 – 1,40,000 million 2 R&D investment: 7-7.25% of total sales 3 EBITDA margin: ~19% 4 Consolidated CAPEX: Rs. 7,000 million 5 Target double-digit PAT margin 17 ©2023 Glenmark Pharmaceuticals Ltd. All Rights Reserved
Slide 19: Glenmark
G Glenmark
Glenmark Pharmaceuticals — Q4 FY24 Earnings Presentation on 6ix